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A skeptical view of assisted home 
peritoneal dialysis
DC Mendelssohn1,2
While assisted PD may prove helpful for a subset of new patients, 
its overall effect will be small. A trend towards a small increase in 
incident PD rate will not translate directly into an equivalent rise in PD 
prevalence. Important questions about cost effectiveness and about 
long-term impact of home PD assistance on modality distribution 
remain unanswered.
Kidney International (2007) 71, 602–604. doi:10.1038/sj.ki.5002153
For enthusiasts of peritoneal dialysis (PD), 
the past decade has been glum. PD utiliza-
tion has been in decline in North Amer-
ica. Reasons that have been suggested are 
the aging of the dialysis population; the 
burden of comorbid and social conditions 
that make home dialysis diffi  cult; overre-
action to the published American mortal-
ity experience with PD as compared with 
hemodialysis (HD); the fi rst two Kidney 
Disease Outcomes Quality Initiative PD 
guidelines, which set relatively high dial-
ysis dose targets for PD (although these 
were recently reduced); economic incen-
tives to keep HD units at full capacity; 
diffi  culties for nephrologists in starting a 
new PD program or in running a small 
one; and fi nally, inadequate training of 
nephrologists in PD. Recent reviews have 
discussed these issues in some detail.1–3
Oliver and colleagues at Sunnybrook 
Health Sciences Centre, Toronto, Can-
ada4 (this issue), report on an approach 
to increasing PD utilization by providing 
marginal candidates with support at home 
by visiting community-based nurses 
(Home Plus Program). A modest increase 
in the number of incident patients on PD 
is described. Th e authors conclude that 
“assisted PD…may be an eff ective strategy 
to reverse the decline in PD.”
Might such an approach provide 
a strong stimulus toward the revival 
of PD?
Unfortunately, my opinion is that 
although this strategy may prove help-
ful for a subset of new patients, its overall 
effect will be small. Sunnybrook’s data 
show that the percentage of patients 
who were considered eligible for PD was 
increased by the availability of home care 
assistance from 65% to 80%.4 However, 
the same percentage of eligible patients 
chose PD in regions where the home care 
support was available as in regions where 
it was not. Although the utilization of PD 
in the incident population was slightly 
higher in the regions where home care 
was available, the diff erence was small 
(47% versus 37%) and not statistically 
signifi cant (P = 0.27).
Th is small increase in incident PD utili-
zation may refl ect a truly negative eff ect of 
assistance or may refl ect a real trend that 
would prove positive if the study had more 
power. Even assuming the latter, such a 
small increase in incident PD rate will 
not translate directly into an equivalent 
rise in PD prevalence because of deaths, 
transplants, and primary and secondary 
PD failures. PD is a less robust chronic 
therapy than HD, and PD failure remains 
a signifi cant issue, with important cost 
implications secondary to transferring to 
HD. Th e Sunnybrook study reports trends 
of higher hospitalization rates, increased 
hospital days, and more modality switches 
(all per patient year) with assisted PD that 
are worrisome in magnitude but are not 
statistically signifi cant. Furthermore, the 
net eff ect of such an increase in incident 
PD rate would take several years before 
reaching a new equilibrium state, but the 
Sunnybrook study, with a mean follow-up 
of 449 days per patient, is too small and 
too short to provide meaningful insight 
into what complication rates really are and 
what the new steady state might look like. 
Th is is a major limitation and should make 
a reader cautious about whether assisted 
PD might reverse the decline.
Th ere are other philosophical and prac-
tical issues that must be considered. Figure 
1 shows a theoretical spectrum of patients 
approaching end-stage renal disease. On 
the left  are patients considered independ-
ent and suitable for home dialysis. On the 
right are those who are dependent and 
unsuitable for home dialysis. Nephrolo-
gists in Canada, the United States, and the 
United Kingdom have all reported that 
an optimal dialysis system would include 
30%–40% of PD patients.5–7 In contrast, 
in 2004, PD utilization was only 7.7% in 
the United States and 18.8% in Canada.8 
Th is suggests that there are many suit-
able patients who ought to be available to 
increase the prevalence of PD and home 
HD. A focus on pushing the home-dialysis 
envelope by shift ing the distribution from 
the left  of the spectrum toward the middle 
would be expected to be very successful 
(Figure 1, scenario A). Indeed, Sunny-
brook’s data show that 65% of patients are 
eligible for PD even without assistance. It 
seems likely that an eff ective strategy that 
converts most of the 65% eligible to actu-
ally start unassisted PD would have a very 
large eff ect.
On the other hand, Sunnybrook’s strat-
egy is to fi nd patients on the right of the 
spectrum and to try to support them 
(and/or their families) such that PD 
becomes viable in a previously ineligible 
subgroup (Figure 1, Sunnybrook sce-
nario). It is not clear that there are many 
such patients who could be success-
fully maintained on PD. Th is approach 
transforms the traditional selection of 
patients for home dialysis from those 
1Department of Nephrology, Humber River 
Regional Hospital, Toronto, Canada; and 
2Department of Medicine, University of Toronto, 
Toronto, Canada
Correspondence: DC Mendelssohn, Humber River 
Regional Hospital, 200 Church Street, 
Room 2024, Weston, Ontario M9N 1N8, Canada. 
E-mail: dmendelssohn@hrrh.on.ca
Kidney International (2007) 71       603
commentar y
who are independent and suitable, to 
those who are not. Even if this is par-
tially successful, the cost is very high. 
Notably, most patients (75%) who were 
off ered assistance utilized that assistance, 
which makes one wonder about overuti-
lization. Although Oliver et al.4 cite an 
average cost based on 4.6 visits per week 
as Can$12,000, at the maximum of two 
visits per day the cost is Can$31,200, 
and PD becomes more expensive than 
in-center HD. Although actual costs of 
dialysis and of home care assistance will 
vary somewhat from jurisdiction to juris-
diction, the truth is that PD in 2007 is not 
very successful despite the well-known 
cost advantages that exist in Canada and 
the United States. First principles suggest 
that it would not be more successful if 
the cost advantage were reduced or even 
eliminated by assisted PD.
PD enthusiasts should be re-examin-
ing the spectrum shown in Figure 1 and 
considering a large and novel future threat 
to PD utilization. It seems that home HD 
(and especially daily home HD) is believed 
by nephrologists to be underutilized.5–7 
Th erefore a rather fundamental question 
must be carefully considered: where will 
these new home HD patients come from? 
Home HD patients are the most inde-
pendent, at the far left  of the spectrum. If 
the new generation of home HD patients 
comes from the PD pool instead of from 
the in-center HD pool, then growth of 
home HD will reduce the prevalence of 
PD (Figure 1, scenario B). Th is seems the 
likeliest scenario, because patients in the 
PD pool are more independent than those 
in center. The PD community should 
think about how to expand the eligible 
pool for both PD and home HD (scenario 
A), rather than focus on PD only, because 
in a direct competition for patients with 
home HD, PD is likely to lose market 
share.
In this regard, we have recently pro-
posed a reformulated integrated-care 
model that promotes live-donor trans-
plantation or home dialysis (PD or home 
HD) for suitable patients.9 Th is approach 
is very consistent with the observation by 
Oliver et al.4 that PD choice was high in 
both the assisted PD region and the con-
trol, unassisted region because a rigorous 
approach to offering PD to all eligible 
patients was applied. Unfortunately, such 
empowerment of patient choice appears 
to be the exception rather than the rule, 
especially in the United States.10,11
The concept of an optimal dialysis-
modality distribution that achieves the 
best patient outcomes, at the lowest cost, 
makes the most sense for any society.12 
Although this is not an easy number to 
calculate by empirical methodology, sur-
veys suggest strongly that there is a fairly 
profound underutilization of home dialy-
sis in North America and in many other 
countries. For home HD, especially daily, 
the factor that most limits growth is a lack 
of adequate funding in many countries. 
Th e introduction of new funding arrange-
ments in Australia, Th e Netherlands, and 
parts of Canada seems likely to allow 
home HD to flourish. For both home 
HD and home PD, the key to growth is to 
identify suitable patients and to provide 
education to them that promotes (but 
does not mandate) less-expensive home-
dialysis choices. As presently described, 
Sunnybrook’s unlimited assisted home PD 
would not seem capable of contributing 
to the evolution of an optimal dialysis-
modality distribution.
Bigger, longer, and better studies of 
assisted PD are warranted. Th ese stud-
ies must be of suffi  cient duration to allow 
insight into the eff ect of assistance on the 
steady state of modality distribution. In 
particular, cost eff ectiveness must be pro-
spectively and rigorously assessed. Per-
haps a more time-limited model of full 
assistance for a month or two, followed 
by partial assistance, with a view toward 
complete independence could be exam-
ined. At fi rst glance, this would appear to 
off er more cost eff ectiveness, and is more 
likely to target potentially independent 
patients, than the Sunnybrook program.
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Figure 1 | A theoretical spectrum of dialysis patients classified by suitability for home 
dialysis. The baseline represents a hypothetical current dialysis-modality distribution. The 
Sunnybrook scenario shows the new region where potential dependent, assisted peritoneal 
dialysis (PD) patients derive from. Scenario A shows the effect of expansion of the pool of patients 
eligible for home dialysis (both hemodialysis (HD) and PD), with growth of both modalities. 
Scenario B represents the growth of home HD, through competition with PD for the existing pool 
of home-eligible patients. PD utilization has decreased.
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Renal ischemia–reperfusion injury: 
Renal dendritic cells loudly sound 
the alarm
PJ Nelson1
Renal ischemia–reperfusion injury is a major cause of acute renal failure 
and kidney allograft dysfunction. Dong and colleagues now identify 
the surveying renal dendritic cell network as the predominant source 
of tumor necrosis factor-α during the early stages of renal ischemia–
reperfusion injury, raising the possibility for direct targeting of renal 
dendritic cells to help ameliorate this common form of renal injury and 
its sequelae.
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Against the physician’s credo “do no 
harm,” renal ischemia–reperfusion injury 
(IRI) stands as an anathema. As if the 
clinical burden from renal IRI second-
ary to other causes isn’t enough, kidney 
transplant care teams everywhere face 
daily the irony that at some point, the 
patient’s remedy, a kidney allograft , must 
fi rst suff er an unavoidable and trouble-
some insult: complete ischemia during 
transfer from the donor to the recipient, 
followed by reperfusion once vascular 
anastomosis in the recipient is complete. 
To counter the jeopardy this poses to 
kidney function in the recipient, inves-
tigators have worked diligently for years 
in clinical settings and in the laboratory 
to understand the pathophysiology of 
renal IRI and to devise ways to lessen its 
detriment to the allograft . Notwithstand-
ing the great strides resulting from these 
eff orts, renal IRI continues to factor into 
delayed graft  function, acute rejection, 
and chronic allograft  nephropathy.
Along the cascade of pathogenic events 
that cause renal IRI, there has been an 
appreciation for the early innate immune 
response within the kidney itself and its 
role in priming the kidney for further 
injury. One puzzling question, however, 
has been which populations of cells resi-
dent within the kidney are most important 
in mediating this ‘sterile’ infl ammatory 
response. Th anks to a study by Dong and 
colleagues1 (this issue), some answers 
are now provided. Dong et al. proceed in 
their research on renal IRI under the pre-
cept that the immediate innate immune 
responses to parenchymal injury any-
where within the kidney are orchestrated 
by resident immune cells, specifi cally renal 
dendritic cells (DCs), that are designed to 
survey for and respond to cellular dam-
age.1 Th is immunologic paradigm was 
recently buttressed by the discovery of 
the contiguous renal DC network in nor-
mal kidney.2 By carefully fractionating 
resident renal DCs from other immune 
and nonimmune renal cells aft er induc-
ing renal IRI, and by selectively ablating 
resident renal DCs with clodronate lipo-
somes before inducing renal IRI, Dong et 
al.1 demonstrate that resident renal DCs 
are the predominant source of intrarenal 
tumor necrosis factor-α (TNF-α) in early 
renal IRI (Figure 1).
Although other cytokines and chem-
okines produced by resident renal DCs 
probably play a role in the pathogen-
esis of renal IRI, the seemingly limited 
focus by Dong et al. on TNF-α1 is well 
founded. Soluble TNF-α can be abun-
dantly expressed by mononuclear phago-
cyte lineages (for example, myeloid DCs 
and macrophages), natural killer cells, 
and certain T-lymphocyte eff ectors (for 
example, T-helper 17 (Th17) and Th1 
lymphocytes) and mediates its effects 
by engaging TNF receptor-1 (TNFR-1), 
which is normally present at basal levels 
on most quiescent cells, and TNFR-2, 
which is normally present on endothelial 
cells and some leukocytes.3 Th is pleio-
tropic reservoir of TNF-α-responsive cell 
types explains TNF-α’s harmful eff ects 
when its synthesis and release are poorly 
controlled.3 During renal IRI in the allo-
graft , for example, the substantial early 
production of TNF-α by resident renal 
DCs1 and the subsequent activation of 
adjacent TNFRs could induce apoptosis of 
renal epithelium,3 and, thus, the genera-
tion of alloantigen, all the while causing 
upregulation of adhesion molecules on 
renal endothelium, thereby promoting 
extravasation of the recipient’s leukocytes 
into the allograft . Among several possi-
bilities, the latter could include preexist-
ing populations of T-lymphocyte eff ectors 
that further propagate renal IRI4 or the 
recipient’s own traffi  cking DCs, ready to 
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